Literature DB >> 9700021

Significance of melanin binding and metabolism in the activity of 5-acetoxyacetylimino-4-methyl-delta2-1,3,4,-thiadiazolin e-2-sulfonamide.

R D Schoenwald1, V Tandon, D E Wurster, C F Barfknecht.   

Abstract

5-Acetoxyacetylimino-4-methyl-delta2-1,3,4,-thiadiazoline -2-sulfonamide (compound (1)) is an ester prodrug that lowered intraocular pressure (IOP) in albino New Zealand rabbits, but was found to be inactive in pigmented Dutch Belt rabbits. In order to explain the differences in pharmacological activity for the two rabbit species, metabolism and melanin binding were studied. Depending on the initial concentration, the binding of compound (1) to natural melanin (Sepia officinalis) was 20-60%. The binding constant, K, at 37 degrees C was 4.32 x 10(5) M(-1) and the maximum moles bound to melanin, r(max), was 4.5 x 10(-7) mol/mg of melanin. From a determination of binding at temperatures between 25 degrees C and 47 degrees C, a van't Hoff plot was constructed to determine enthalpy and entropy changes accompanying the binding process, deltaH and deltaS, respectively. Values calculated from the plot were -12.7 and -15.4 kcal/(mol deg), respectively. Negative values for these parameters are consistent with charge transfer interactions and therefore suggest that this may be an operative mechanism between compound (1) and melanin. The in vitro incubation of compound (1) was also studied with various ocular tissues from both albino and pigmented rabbits which were iris-ciliary body, intact cornea, stroma/endothelium and aqueous humor. A major metabolite, MET 1, was identified and also observed from in vivo analyses of the same tissues following topical application. The metabolite was isolated and subjected to mass spectroscopy and proton nuclear magnetic resonance spectroscopy analysis. From these analyses, it was hypothesized that the formation of MET 1 involved a GSH conjugation mechanism which displaced the sufonamide (-SO2NH2) group. The metabolism was found to be less extensive in the pigmented rabbit than in the albino rabbit and suggested that the binding affinity of compound (1) for melanin was a better explanation for the lack of IOP activity in the pigmented rabbit than differences in metabolism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9700021     DOI: 10.1016/s0939-6411(97)00166-5

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  7 in total

Review 1.  Ocular drug delivery.

Authors:  Ripal Gaudana; Hari Krishna Ananthula; Ashwin Parenky; Ashim K Mitra
Journal:  AAPS J       Date:  2010-05-01       Impact factor: 4.009

Review 2.  Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.

Authors:  Uday B Kompella; Aniruddha C Amrite; Rashmi Pacha Ravi; Shelley A Durazo
Journal:  Prog Retin Eye Res       Date:  2013-04-17       Impact factor: 21.198

3.  Effect of eye pigmentation on transscleral drug delivery.

Authors:  Narayan P S Cheruvu; Aniruddha C Amrite; Uday B Kompella
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-01       Impact factor: 4.799

4.  Binding of memantine to melanin: influence of type of melanin and characteristics.

Authors:  Martin J Koeberle; Patrick M Hughes; Graham G Skellern; Clive G Wilson
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

5.  Solid Lipid Nanoparticles Improve the Diclofenac Availability in Vitreous after Intraocular Injection.

Authors:  Mojtaba Abrishami; Majid Abrishami; Asma Mahmoudi; Navid Mosallaei; Mohammad Vakili Ahrari Roodi; Bizhan Malaekeh-Nikouei
Journal:  J Drug Deliv       Date:  2016-10-10

Review 6.  Nanoparticle-Mediated Delivery of Neuroprotective Substances for the Treatment of Diabetic Retinopathy.

Authors:  Rosario Amato; Massimo Dal Monte; Matteo Lulli; Vittoria Raffa; Giovanni Casini
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

Review 7.  Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations.

Authors:  Rubén Varela-Fernández; Victoria Díaz-Tomé; Andrea Luaces-Rodríguez; Andrea Conde-Penedo; Xurxo García-Otero; Asteria Luzardo-Álvarez; Anxo Fernández-Ferreiro; Francisco J Otero-Espinar
Journal:  Pharmaceutics       Date:  2020-03-16       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.